Drug Profile
Sutimlimab - Bioverativ
Alternative Names: BIVV 009; Enjaymo; Sutimlimab-jome; TNT 009Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator iPierian
- Developer Bioverativ; Sanofi
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action Complement C1s inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Autoimmune haemolytic anaemia
- Discontinued Idiopathic thrombocytopenic purpura
Most Recent Events
- 08 Jun 2023 Safety and efficacy data from the part B of the phase III CADENZA trial in cold agglutinin disease presented at the 28th Congress of the European Hematology Association (EHA-2023)
- 08 Jun 2023 Updated safety and efficacy data from the phase III CADENZA trial in Autoimmune haemolytic anaemia presented at the 28th Congress of the European Hematology Association (EHA-2023)
- 08 Jun 2023 Efficacy data from a phase III Cadenza trial in Autoimmune haemolytic anaemia presented at the 28th Congress of the European Haematology Association (EHA-2023)